“…CBD acts through the cannabinoid CB1 and CB‐2 receptors, three G protein coupled‐receptors (adenosine receptor subtype 2A, serotonin receptor subtype 1A and G protein‐coupled receptor 55), one ligand‐gated ion channel (transient receptor potential vanilloid channel‐1, TRPV‐1) and one nuclear factor (peroxisome proliferator‐activated receptor γ, PPAR). CBD has been used in the management of epilepsy, 353 , 354 Alzheimer's disease, 355 pain alleviation in MS, 307 neurological responses in Parkinson's disease, 308 , 313 chronic pain 305 , 306 , 309 , 312 including LBP. 311 CBD has been evaluated in a double blind randomized clinical trial for the relief of central neuropathic pain in MS. 307 …”